<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2305233690
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CINAC 60 MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CINACALCET
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        498
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Abdi Ibrahim Ilac San ve Tic A.S." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Abdi Ibrahim Ilac San ve Tic A.S.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H05BX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Cinac works by controlling the levels of parathyroid hormone (PTH), calcium and phosphorus in your body. It is used to treat problems with organs called parathyroid glands. The parathyroids are four small glands in the neck, near the thyroid gland, that produce parathyroid hormone (PTH).</p><p style="text-align:justify">Cinac&nbsp;is used:<br />&bull; to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products.<br />&bull; to reduce high levels of calcium in the blood (hypercalcaemia) in patients with parathyroid cancer.<br />&bull; to reduce high levels of calcium in the blood (hypercalcaemia) in patients with primary hyperparathyroidism who still have high calcium levels after removal of the parathyroid gland or when removal of the gland is not possible.</p><p style="text-align:justify">In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroids glands. &quot;Primary&quot; means that the hyperparathyroidism is not caused by any other condition and &quot;secondary&quot; means that the hyperparathyroidism is caused by another condition, e.g., kidney disease. Both primary and secondary hyperparathyroidism can cause the loss of calcium in the bones, which can lead to bone pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>Do not take Cinac</strong><br />- if you are allergic to Cinacalcet or any of the other ingredients of this medicine (listed in section 6).</p><p style="text-align:justify"><strong>Warnings and precautions</strong></p><p style="text-align:justify">Talk to your doctor, pharmacist or nurse before taking Cinac.</p><p style="text-align:justify">Before you start taking Cinac, tell your doctor if you have or have ever had:<br />&bull; seizures (fits or convulsions). The risk of having seizures is higher if you have had them before;<br />&bull; liver problems;<br />&bull; heart failure.</p><p style="text-align:justify">Life threatening events and fatal outcomes associated with low calcium levels (hypocalcaemia) have been reported in patients treated with Cinacalcet.</p><p style="text-align:justify">Low calcium levels can have an effect on your heart rhythm. Tell your doctor if you experience an unusually fast or pounding heartbeat, if you have heart rhythm problems, or if you take medicines known to cause heart rhythm problems, while taking Cinacalcet.</p><p style="text-align:justify">For additional information see section 4.</p><p style="text-align:justify">During treatment with Cinac, tell your doctor:<br />&bull; if you start or stop smoking, as this may affect the way Cinacalcet works.</p><p style="text-align:justify"><strong>Children and adolescents</strong><br />Children under the age of 18 must not take Cinac.</p><p style="text-align:justify"><strong>Other medicines and Cinac</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p style="text-align:justify">Tell your doctor if you are taking the following medicines.</p><p style="text-align:justify">Medicines such as these can affect how Cinacworks:<br />&bull; medicines used to treat skin and fungal infections (ketoconazole, itraconazole and voriconazole);<br />&bull; medicines used to treat bacterial infections (telithromycin, rifampicin and ciprofloxacin);<br />&bull; a medicine used to treat HIV infection and AIDS (ritonavir);<br />&bull; a medicine used to treat depression (fluvoxamine).</p><p style="text-align:justify">Cinac may affect how medicines such as the following work:<br />&bull; medicines used to treat depression (amitriptyline, desipramine, nortriptyline and clomipramine);<br />&bull; medicines used to treat changes in heart rate (flecainide and propafenone);<br />&bull; a medicine used to treat high blood pressure (metoprolol);</p><p style="text-align:justify"><strong>Cinac with food and drink</strong><br />Cinac should be taken with or shortly after food.</p><p style="text-align:justify"><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p style="text-align:justify">Cinacalcet has not been tested in pregnant women. In case of pregnancy, your doctor may decide to modify your treatment, as Cinacalcet might harm the unborn baby.</p><p style="text-align:justify">It is not known whether Cinacalcet is excreted in human milk. Your doctor will discuss with you if you should discontinue either breast-feeding or treatment with Cinac.</p><p style="text-align:justify"><strong>Driving and using machines</strong><br />No studies on the effects on the ability to drive and use machines have been performed. Dizziness and seizures have been reported by patients taking Cinacalcet. If you experience these, your ability to drive or operate machinery may be affected.</p><p style="text-align:justify"><strong>Cinac contains lactose</strong><br />If you have been told&nbsp;by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will tell you how much Cinacalcet you must take.</p><p style="text-align:justify">Cinac must be taken orally, with or shortly after food. The tablets must be taken whole and are not to be divided.</p><p style="text-align:justify">Your doctor will take regular blood samples during treatment to monitor your progress and will adjust your dose if necessary.</p><p style="text-align:justify"><strong>If you are being treated for secondary hyperparathyroidism</strong><br />The usual starting dose for Cinacis 30 mg (one tablet) once per day.</p><p style="text-align:justify"><strong>If you are being treated for parathyroid cancer or primary hyperparathyroidism</strong></p><p style="text-align:justify">The usual starting dose for Cinacis 30 mg (one tablet) twice per day.</p><p style="text-align:justify"><strong>If you take more Cinacthan you should</strong><br />If you take more Cinacthan you should you must contact your doctor immediately. Possible signs of overdose include numbness or tingling around the mouth, muscle aches or cramps and seizures.</p><p style="text-align:justify"><strong>If you forget to take Cinac</strong><br />Do not take a double dose to make up for a forgotten dose.</p><p style="text-align:justify">If you have forgotten a dose of Cinac, you should take your next dose as normal.</p><p style="text-align:justify">If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="text-align:justify">If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures you <strong>should tell you doctor immediately.</strong>&nbsp;These may be signs that your calcium levels are too low (hypocalcaemia).</p><p style="text-align:justify"><strong>Very common: may affect more than 1 in 10 people</strong><br />&bull; nausea and vomiting, these side effects are normally quite mild and do not last for long.</p><p style="text-align:justify"><strong>Common: may affect up to 1 in 10 people</strong><br />&bull; dizziness<br />&bull; numbness or tingling sensation (paraesthesia)<br />&bull; loss (anorexia) or decrease of appetite<br />&bull; muscle pain (myalgia)<br />&bull; weakness (asthenia)<br />&bull; rash<br />&bull; reduced testosterone levels<br />&bull; high potassium levels in the blood (hyperkalemia)<br />&bull; allergic reactions (hypersensitivity)<br />&bull; headache<br />&bull; seizures (convulsions or fits)<br />&bull; low blood pressure (hypotension)<br />&bull; upper respiratory infection<br />&bull; breathing difficulties (dyspnoea)<br />&bull; cough<br />&bull; indigestion (dyspepsia)<br />&bull; diarrhoea<br />&bull; abdominal pain, abdominal pain - upper<br />&bull; constipation<br />&bull; muscle spasms<br />&bull; back pain<br />&bull; low calcium levels in the blood (hypocalcaemia).</p><p style="text-align:justify"><strong>Not known: frequency cannot be estimated from available data</strong><br />&bull; hives (urticaria)<br />&bull; swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema).<br />&bull; unusually fast or pounding heart beat which may be associated with low levels of calcium in your blood (QT prolongation and ventricular arrhythmia secondary to hypocalcaemia).</p><p style="text-align:justify">After taking Cinacalcet a very small number of patients with heart failure had worsening of their condition and/or low blood pressure (hypotension).</p><p style="text-align:justify"><strong>Children and adolescents</strong><br />The use of Cinacalcet in children and adolescents has not been established. A fatal outcome was reported in an adolescent clinical trial patient with very low calcium levels in the blood (hypocalcaemia).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Keep this medicine out of the sight and reach of children.</p><p style="text-align:justify">Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions.</p><p style="text-align:justify">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">- The active substance is Cinacalcet. Each film-coated tablet contains 30mg, 60mg or 90mg of Cinacalcet (as hydrochloride).<br />- The other ingredients are lactose monohydrate, microcrystalline cellulose, pregelatinized starch, crospovidone, magnesium stearate and talc.<br />- The tablets are coated with SheffCoat green (containing hypromellose, titanium dioxide (E171), lactose<br />monohydrate, triacetin/glycerol triacetate, yellow iron oxide (E172) and FD&amp;C Blue#2/ indigotine aluminium lake (E132)).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cinac is a light green film-coated tablet. They are oval-shaped and have 'C' marked on one side and '30', '60' or '90' on the other side.
Cinac is available in blisters of 30 mg, 60 mg or 90 mg film-coated tablets. Each blister pack contains either 14, 28 or 84 tablets in a carton.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Marketing Authorisation Holder<br />AJA Pharmaceutical Industries Company, Ltd.<br />Building no. 6979, Hail Industrial City, Hail 55414<br />Saudi Arabia<br />Tel: +966 11 268 7900</p><p style="text-align:justify">Manufacturer<br />Abdi Ibrahim IlacSanayi<br />Reşitpaşa Mahallesi,, Eski B&uuml;y&uuml;kdere Caddesi,Sariyer<br />İstanbul, 34467, Turkey<br />Tel: +902123668400</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 03/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="text-align:justify">يعمل سيناك ويؤدي مفعوله من خلال السيطرة على مستويات الهرمون جار الدرقي (PTH) وبالتالي تنظيم مستويات الكالسيوم والفسفور في الجسم. وهو يستعمل لعلاج المشاكل في الأعضاء المسماة &quot;الغدد جارة الدرقية&quot; والغدد جارة الدرقية&nbsp;&nbsp;هي 4 غدد صغيرة في العنق بجوار الغدة الدرقية وتفرز الهرمون جار الدرقي (PTH).</p><p style="text-align:justify">يستعمل سيناك في:</p><p style="text-align:justify">- علاج فرط نشاط الغدة الجار درقية الثانوي لدى المرضى المصابين بمشاكل أو أمراض خطيرة في الكلى الذي يحتاجون للعلاج بغسيل الدم لتنقية الدم من النواتج والفضلات التي يراد التخلص منها.</p><p style="text-align:justify">- خفض مستويات الكالسيوم في الدم لدى المرضى المصابين بسرطان الغدة الجار درقية.</p><p style="text-align:justify">- خفض مستويات الكالسيوم في الدم لدى المرضى المصابين بفرط نشاط الغدة الجار الدرقية، الذين تبقى مستويات الكالسيوم في دمهم مرتفعة بعد استئصال الغدة الدرقية أو الذين لايمكن استئصال غدتهم الجار درقية.</p><p style="text-align:justify">في كل من الفرط الأولي والثانوي في نشاط الغدة الجار درقية يتم إنتاج كميات زائدة من الهرمون جار درقي (PTH) بواسطة الغدد الجار درقية.&nbsp;المصطلح أولي&quot; يعنى أن النشاط الزائد للغدد الجار درقية&nbsp;&nbsp;غير ناتج عن حالات أو أمراض اخرى، أما المصطلح &quot;ثانوي&quot; فيعنى أن النشاط الزائد للغدد الجار درقية&nbsp;&nbsp;ناتج عن حالات أو أمراض اخرى مثل مرض الكلى على سبيل المثال. وكل من فرط النشاط الأولي والثانوي يمكن أن يؤدي إلى فقدان الكالسيوم من العظام مما يؤدي إلى آلام وكسور فى العظام إضافة&nbsp;&nbsp;إلى مشاكل في الدم والقلب والأوعية الدموية وحصوات فى الكلى وأمراض عقلية وفقدان الوعي&nbsp;(الغيبوبة).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">لا تتناول سيناك إذا كانت لديك حساسية لسيناكالسيت أو أي من مكونات هذا الدواء (المدرجة فى الفقرة رقم -3).&nbsp;</p><p style="text-align:justify">تحذيرات واحتياطات<br />يجب عليك استشارة الطبيب أو الصيدلى قبل البدء فى استعمال سيناك&nbsp;وعليك كذلك ابلاغ الطبيب إذا كنت مصابا أو سبق ان اصبت بأي من الحالات التالية:&nbsp;<br />- التشنجات (نوبات تقلص أو ارتعاش عضلى): تزداد مخاطر حدوث التشنجات إذا كنت قد تعرضت لها فى السابق.<br />- مشاكل في الكبد.<br />- فشل القلب.&nbsp;</p><p style="text-align:justify">وقد وردت تقارير عن نتائج قاتلة مرتبطة بانخفاض مستويات الكالسيوم لدى مرضى تناولوا دواء سيناكالسيت.&nbsp;&nbsp;ويمكن أن تؤثر مستويات الكالسيوم المنخفضة على انتظام نبض القلب. ولذلك يجب ابلاغ الطبيب إذا كنت تستعمل سيناكالست&nbsp;ولاحظت أن نبض القلب قد تسارع بشكل غير&nbsp;طبيعي أو أي مشاكل تتعلق بانتظام النبض أو إذا كنت تستعمل أي أدوية من المعروف&nbsp;انها تؤثر في انتظام النبض (انظر الفقرة رقم- ٤).&nbsp;</p><p style="text-align:justify">اثناء استعمال سيناك، يجب إبلاغ الطبيب إذا بدأت التدخين أو توقفت عنه حيث أن ذلك يمكن أن يؤثر فى طريقة عمل سيناكالسن&nbsp;</p><p style="text-align:justify">الأطفال والمراهقون<br />يحب عدم إعطاء سيناك للأطفال والمراهقين الذين تقل أعمارهم عن ١٨ عاما.&nbsp;</p><p style="text-align:justify">الأدوية الأخرى و سيناك<br />يرجى استشارة الطبيب أو الصيدلي إذا كنت تستعمل أو استعملت حديثا او يتوقع ان تستخدم أي&nbsp;أدوية أخرى بما فيه تلك الأدوية التى يمكن الحصول عليها بدون وصفة طبية.&nbsp;</p><p style="text-align:justify">ومن المهم بصورة خاصة ان تبلغ الطبيب اذا كنت تستخدم اي من الأدوية المذكورة&nbsp;أدناه حيث أنها يمكن أن تؤثر في طريقة عمل سيناك:&nbsp;<br />- الأدوية التى تستعمل لعلاج الفطريات الجدية والإصابات العطرية بشكل عام&nbsp;(كيتوكودازول، انتراكودازول، فوربكونازول).&nbsp;<br />- الأدوية التى تستعمل لعلاج الإصابات البكتيرية (تيليثرومايسين، سبروفلوكساسين).&nbsp;<br />- دواء يستعمل لعلاج الإصابة بفيروس HIV ومرض الإيدز (ريتونافير).&nbsp;<br />- دواء يستعمل لعلاج الإكتئاب (فلوكسامين).&nbsp;</p><p style="text-align:justify">سيناك يمكن أن يؤثر على طريقة عمل الأدوية التالية:&nbsp;<br />- أدوية تستعمل لعلاج الاكتئاب (أميتربتولين، ديسيبرامين، نوتريبتالين، كلوميبرامين).&nbsp;<br />- أدوية تستعمل لعلاج مشاكل فى نبض القلب (فليكانيد، بروبافينون).&nbsp;<br />- دواء يستعمل لعلاج ارتفاع ضعط الدم (ميتوبرولول).&nbsp;</p><p style="text-align:justify">سيناك مع الأطعمة والمشروبات<br />يجب تناول سيناك مع الطعام أو بعده بفترة قصيرة.&nbsp;</p><p style="text-align:justify">الحمل والإرضاع<br />بالنسبة للنساء فى حالة الحمل أو احتمال الحمل او التخطيط لحدوث الحمل. يجب&nbsp;استشارة&nbsp;الطبيب أو الصيدلي للنصح والإرشاد قبل البدء فى استعمال هذا الدواء. فإنه لم يتم اختبار سيناكالسيت على نساء حوامل. وفي حالة الحمل ربما يقرر الطيب تعديل العلاج&nbsp;<br />حيث أن سيناكالسيت يمكن ان يسبب الضرر للجنين.&nbsp;</p><p style="text-align:justify">ولا يعرف ما إذا كان سيناك يفرز فى حليب الأم أم لا، لدلك فإن النساء المرضعات او اللاتى&nbsp;يخططن للإرضاع يجب عليهن استشارة الطبيب الذى قد يقرر التوقف عن الإرضاع أو وقف&nbsp;تناول سيناك.&nbsp;</p><p style="text-align:justify">قيادة المركبات وتشغيل الآلات<br />لم يتم إجراء دراسات حول تأثر استعمال هذا الدواء في القدرة على قيادة المركبات وتشغيل&nbsp;الآلات.&nbsp;</p><p style="text-align:justify">ولكن قد تم الإبلاغ عن اعراض نعاس ودوار لدى مرضى يستعملون سيناكالسنت، وإذا لاحظت أيا&nbsp;تلك الأعراض فيجب عليك عدم قيادة اي مركبات او تشغيل الآلات.&nbsp;</p><p style="text-align:justify">سيناك يحتوي على اللاكتوز<br />إذا كان طبيبك قد ابلغك بأن لديك عدم تقبل لبعض أنواع السكريات فيجب عليك الإتصال&nbsp;بالطبيب قبل تداول هذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">يجب عليك دائما استعمال هذا الدواء حسب تعليمات الطبيب أو الصيدلي تماما. إذا كنت غير متأكد فيجب عليك الإتصال بالطبيب أو الصيدلي.&nbsp;</p><p style="text-align:justify">يجب أن يؤخذ سيناك بالفم مع الطعام أو بعد تناول الطعام مباشرة.&nbsp;ويجب ان تؤخذ الأقراص كاملة دون تقسيمها.&nbsp;</p><p style="text-align:justify">اثناء فترة العلاج سيقوم الطبيب بأخذ عينات من دمك لتقييم مدى تطور الحالة وسيقوم بتعديل&nbsp;الجرعة إذا رأى أن ذلك ضروري.&nbsp;</p><p style="text-align:justify">إذا كنت تعاني من فرط النشاط الثانوى للغدة الجار درقية:<br />الجرعة الموصى بها من سيناك هى ٣٠ ملغم (قرص واحد) مرة واحدة في اليوم.&nbsp;</p><p style="text-align:justify">إذا كنت تعاني من سرطان الغدة الجار درقية أو من فرط النشاط الأولي للغدة الجار درقية:&nbsp;<br />الجرعة الموصى بها من سيناك هى ٣٠ ملغم (قرص واحد) مرتين في اليوم.&nbsp;</p><p style="text-align:justify">إذا تناولت جرعة زائدة من سيناك:&nbsp;<br />إذا تناولت جرعة زائدة عن ما وصفه الطبيب فيجب عليك الاتصال بالطبيب فورا.&nbsp;</p><p style="text-align:justify">الأعراض&nbsp;المحتملة لزيادة الجرعة تشمل الخدر او التنميل حول الفم وآلام بالعضلات او تقلصات عضلية وتشنجات.&nbsp;</p><p style="text-align:justify">اذا نسيت أن تتناول سيناك:&nbsp;<br />إدا نسيت ان تتناول الجرعة المعتادة من سيناك فى وقتها فيجب أن لا تأخذ جرعة اخرى&nbsp;لتعويضها وعليك ان تأخذ الجرعة التالية التى حل موعدها وواصل الاستعمال كالمعتاد.&nbsp;</p><p style="text-align:justify">إذا كانت لديك أي اسئلة أو استفسارات حول استعمال هذا الدواء فيجب عليك استشارة الطبيب أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">هذا الدواء كغيره من الأدوية يمكن أن يسبب بعض الآثار الجانبية مع انها لا تحدث لدى جميع الأشخاص.&nbsp;</p><p style="text-align:justify">إذا بدأت تشعر بالخدر أو التنميل حول الفم أو آلام بالعضلات أو تقلصات عضلية وتشنجات&nbsp;فيجب عليك إبلاغ الطبيب فورا. فهذه الأعراض قد تكون علامات على انخفاص مستوى الكالسيوم&nbsp;في الدم.&nbsp;</p><p style="text-align:justify">تأثيرات جانبية شائعة جدا (يمكن أن تصيب ما يزيد عن ١ من بين كل ١٠ أشخاص):&nbsp;<br />- غثيان وتقيؤ وهي أعراض خفيفة فى العادة ولا تستمر طويلا.&nbsp;</p><p style="text-align:justify">تأثيرت جانبية شائعة (يمكن أن تصيب لغاية ١ من بين كل ١٠ أشخاص):&nbsp;<br />- دوار<br />- احساس بالخدر أو التنميل.&nbsp;<br />- فقدان او ضعف الشهية.&nbsp;<br />- ألم بالعضلات.&nbsp;<br />- ضعف او وهن.&nbsp;<br />- طفح جلدي.&nbsp;<br />- نقص مستويات هرمون التستوستيرون.&nbsp;<br />- ارتقاع مستويات البوتاسيوم فى الدم.&nbsp;<br />- ردود فعل حساسية.&nbsp;<br />- صداع.&nbsp;<br />- تشنجات (تقلصات أو ارتعاشات عضلية).&nbsp;<br />- انخفاض ضغط الدم.&nbsp;<br />- التهاب (عدوى) بالحهاز التنفسي العلوي.&nbsp;<br />- صعوبة او ضيق فى التنفس.&nbsp;<br />- سعال.&nbsp;<br />- عسر الهضم.&nbsp;<br />- إسهال.&nbsp;<br />- ألم بالبطن عموما أو فى أعلى البطن.&nbsp;<br />- إمساك.&nbsp;<br />- تقلصات عضلية.&nbsp;<br />- ألم بالظهر.&nbsp;<br />- انخفاض مستويات الكالسيوم في الدم.&nbsp;</p><p style="text-align:justify">تأثيرت جانبية معدلها غير معروف: لا يمكن تحديد معدلات حدوثها من واقع البيانات المتوفرة:&nbsp;<br />- حكة شديدة (ارتيكاريا)&nbsp;<br />- تورم الوجه أو الشفتين أو اللسان أو الحلق مما قد يسبب صعوبة فى البلع أو التنفس (وذمة وعائية).&nbsp;<br />- أعراض التسارع فى النبض او الزيادة فى قوة النبضات قد تصاحب انخفاض مستويات&nbsp;الكالسيوم في الدم (زيادة في طول فترة موحات &quot;كيو تي&quot; وعدم انتظام نبض بطيني ناتج عن انخفاض الكالسيوم في الدم).&nbsp;</p><p style="text-align:justify">لوحظ أن هناك عدد قليل من المرضى المصابين بفشل القلب قد زادت حالتهم سوءا و /أو نديهم انخفاض فى ضعط الدم بعد استعمال سيناكالسيت.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">احفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.&nbsp;<br />لا تستعمل هذا الدواء بعد تاريخ انتهاء صلاحيته المطبوع على العلبة وهو يشير إلى آخر يوم في ذلك الشهر.&nbsp;<br />هذا المنتج الدوائي لا يحتاج إلى شروط تخزين خاصة.&nbsp;<br />لا تلقي بأي دواء فى مياه الصرف الصحي أو في النفايات المنزلية. وعليك ان تسأل الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاجها. وهذه التدابير تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">المادة الفعالة هى &quot;سيناكالسنت&quot;.&nbsp;<br />كل قرص مغلف يحتوي على ٣٠ملغم، أو ٦٠ملغم، أو ٠ ٩ملغم من مادة سيناكالسيت (على شكل هيدروكلوريد)&nbsp;<br />المكونات الأخرى هي لاكتوز احادي مائى، سليولوز مبلور دقيق، نشا كيتوني، كروسبوفيدون، ستيارات المغنيسيوم، تالك.&nbsp;<br />الأقراص مغلفة بغلاف شيف كوت أخضر (يحتوي على هيبروميلوز ، ثانى اكسيد التيتانيوم (إي ١٧١)، لاكتور احادي مائى، ثلاثي اسيتين / ثلاثي اسيتات الجلسرول، اكسيد الحديد الأصفر (إي ١٧٢) FD&amp;C ازرق رقم ٢ / انديجوتين الومنيوم ليك (إي ١٣٢).&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">هو أقراص مغلفة بلون أخضر فاتح وهي بيضاوية الشكل ومكتوب عليها الحرف &quot;C&quot; على أحد الوجهين والرقم 30 أو 60 أو 90 على الوجه الآخر .&nbsp;<br />يتوفر سيناك المنتج في شرائح تحتوي على أقراص ٣٠ملغم، أو ٦٠ملغم، أو ٠ ٩ملغم وكل عبوة شرائح تحتوي على ٢٨ قرص فى علبة كرتون.&nbsp;</p><p style="text-align:justify">وقد لا يتم تسويق جميع احجام العبوات&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التسويق:&nbsp;<br />شركة أجا للصناعات الدوائية المحدودة&nbsp;<br />المدينة الصناعية حائل- المملكة العربية السعودية&nbsp;<br />رقم المبنى 6979<br />الر ياض 55414&nbsp;<br />تلفون: +966 11 268 7900</p><p>الشركة المصنعة:&nbsp;<br />شركة ابدي ابراهيم<br />اسطنبول- تركيا&nbsp;<br />تلفون: +902123668400</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 01/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cinac 30 mg film-coated tablets. 
Cinac 60 mg film-coated tablets. 
Cinac 90 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet of Cinac 30 mg contains 30 mg cinacalcet (as hydrochloride). 
Each tablet of Cinac 60 mg contains 60 mg cinacalcet (as hydrochloride). 
Each tablet of Cinac 90 mg contains 90 mg cinacalcet (as hydrochloride).
Excipient(s) with known effect:
Each film coated tablet of Cinac 30mg contains 67.2 mg of lactose monohydrate.
 Each film coated tablet of Cinac 60mg contains 134.3 mg of lactose monohydrate. 
Each film coated tablet of Cinac 90mg contains 202.0 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Light green, oval, biconvex film-coated tablet of 9.6-10.0 mm length debossed 'C' on one side and '30' on the other. Light green, oval, biconvex film-coated tablet of 12.3-12.7 mm length debossed 'C' on one side and '60' on the other. Light green, oval, biconvex film-coated tablet of 14.05-14.45 mm length debossed 'C' on one side and '90' on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.</p><p style="text-align:justify"><em>Cinac </em>may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).</p><p style="text-align:justify">Reduction of hypercalcaemia in patients with:</p><ul><li style="text-align: justify;">&nbsp;parathyroid carcinoma.</li><li style="text-align: justify;">primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (asdefined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Secondary hyperparathyroidism</u></p><p style="text-align:justify"><em>Adults and elderly (&gt; 65 years)</em></p><p style="text-align:justify">The recommended starting dose for adults is 30 mg once per day. <em>Cinac </em>should be titrated every 2 to 4 weeks to a maximum dose of 180 mg once daily to achieve a target parathyroid hormone (PTH) in dialysis patients of between 150- 300 pg/ml (15.9-31.8 pmol/l) in the intact PTH (iPTH) assay. PTH levels should be assessed at least 12 hours after dosing with <em>Cinac. </em>Reference should be made to current treatment guidelines.</p><p style="text-align:justify">PTH should be measured 1 to 4 weeks after initiation or dose adjustment of <em>Cinac. </em>PTH should be monitored approximately every 1-3 months during maintenance. Either the intact PTH (iPTH) or bio- intact PTH (biPTH) may be used to measure PTH levels; treatment with cinacalcet does not alter the relationship between iPTH and biPTH.</p><p style="text-align:justify">During dose titration, serum calcium levels should be monitored frequently, and within 1 week of initiation or dose adjustment of <em>Cinac. </em>Once the maintenance dose has been established, serum calcium should be measured approximately monthly. If serum calcium levels decrease below the normal range, appropriate steps should be taken, including adjustment of concomitant therapy (see section 4.4).</p><p style="text-align:justify"><em>Paediatric population</em></p><p style="text-align:justify"><em>Cinac </em>is not indicated for use in children and adolescents due to a lack of data on safety and efficacy (see section 4.4).</p><p style="text-align:justify"><u>Parathyroid carcinoma and primary hyperparathyroidism</u></p><p style="text-align:justify"><em>Adults and elderly (&gt; 65 years)</em></p><p style="text-align:justify">The recommended starting dose of <em>Cinac </em>for adults is 30 mg twice per day. The dose of <em>Cinac </em>should be titrated every 2 to 4 weeks through sequential doses of 30 mg twice daily, 60 mg twice daily, 90 mg twice daily, and 90 mg three or four times daily as necessary to reduce serum calcium concentration to or below the upper limit of normal. The maximum dose used in clinical trials was 90 mg four times daily.</p><p style="text-align:justify">Serum calcium should be measured within 1 week after initiation or dose adjustment of <em>Cinac</em>. Once maintenance dose levels have been established, serum calcium should be measured every 2 to 3 months. After titration to the maximum dose of cinacalcet, serum calcium should be periodically monitored; if clinically relevant reductions in serum calcium are not maintained, discontinuation of cinacalcet therapy should be considered (see section 5.1).</p><p style="text-align:justify"><em>Paediatric population</em></p><p style="text-align:justify"><em>Cinac </em>is not indicated for use in children and adolescents due to a lack of data on safety and efficacy (see section 4.4).</p><p style="text-align:justify"><em>Hepatic impairment</em></p><p style="text-align:justify">No change in starting dose is necessary. <em>Cinac </em>should be used with caution in patients with moderate to severe hepatic impairment and treatment should be closely monitored during dose titration and continued treatment (see sections 4.4 and 5.2).</p><p style="text-align:justify"><strong>Method of administration</strong></p><p style="text-align:justify">For oral use. It is recommended that cinacalcet be taken with food or shortly after a meal, as studies have shown that bioavailability of cinacalcet is increased when taken with food (see section 5.2). Tablets should be taken whole and not divided.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Cinacalcet treatment should not be initiated in patients with a serum calcium (corrected for albumin) below the lower limit of the normal range.</p><p style="text-align:justify">Life threatening events and fatal outcomes associated with hypocalcaemia have been reported in adult and paediatric patients treated with cinacalcet. Manifestations of hypocalcaemia may include paraesthesias, myalgias, cramping, tetany and convulsions. Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia secondary to hypocalcaemia. Cases of QT prolongation and ventricular arrhythmia have been reported in patients treated with cinacalcet (see section 4.8). Caution is advised in patients with other risk factors for QT prolongation such as patients with known congenital long QT syndrome or patients receiving medicinal products known to cause QT prolongation.</p><p style="text-align:justify">Since cinacalcet lowers serum calcium, patients should be monitored carefully for the occurrence of hypocalcaemia (see section 4.2). Serum calcium should be measured within 1 week after initiation or dose adjustment of <em>Cinac. </em>Once the maintenance dose has been established, serum calcium should be measured approximately monthly.</p><p style="text-align:justify">In the event that serum calcium levels fall below 8.4 mg/dl (2.1 mmol/l) and/or symptoms of hypocalcaemia occur the following management is recommended:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Serum calcium value or clinical symptoms of hypocalcaemia</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Recommendations</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&lt; 8.4 mg/dl (2.1 mmol/l) and&gt;7.5 mg/dl (1.9 mmol/l), or in the presence of clinical symptoms of hypocalcaemia</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Calcium-containing phosphate binders, vitamin D sterols and/or adjustment of dialysis fluid calcium concentrations can be used</p><p style="text-align:justify">to raise serum calcium according to clinical judgment.</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&lt; 8.4 mg/dl (2.1 mmol/l) and &gt; 7.5 mg/dl (1.9 mmol/l) or persistent symptoms of hypocalcaemia despite attempts to increase serum calcium</p></td><td style="vertical-align:top"><p style="text-align:justify">Reduce or withhold dose of cinacalcet.</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&lt; 7.5 mg/dl (1.9 mmol/l) or persistent symptoms of hypocalcemia and Vitamin D cannot be increased</p></td><td style="vertical-align:top"><p style="text-align:justify">Withhold administration of cinacalcet until serum calcium levels reach 8.0 mg/dl (2.0 mmol/l) and/or symptoms of hypocalcaemia have resolved.</p><p style="text-align:justify">Treatment should be reinitiated using the next lowest dose of</p><p style="text-align:justify">cinacalcet.</p></td></tr></tbody></table><p style="text-align:justify">In CKD patients receiving dialysis who were administered cinacalcet, approximately 30% of patients had at least one serum calcium value less than 7.5 mg/dl (1.9 mmol/l).</p><p style="text-align:justify">Cinacalcet is not indicated for CKD patients not on dialysis. Investigational studies have shown that CKD patients not on dialysis treated with cinacalcet have an increased risk for hypocalcaemia (serum calcium levels &lt; 8.4 mg/dl [2.1 mmol/l]) compared with cinacalcet-treated CKD patients on dialysis, which may be due to lower baseline calcium levels and/or the presence of residual kidney function.</p><p style="text-align:justify"><strong>Seizures</strong></p><p style="text-align:justify">In clinical studies seizures were observed in 1.4% of cinacalcet treated patients and 0.7% of placebo-treated patients. While the basis for the reported difference in seizure rate is not clear, the threshold for seizures is lowered by significant reductions in serum calcium levels.</p><p style="text-align:justify"><strong>Hypotension and/or worsening heart failure</strong></p><p style="text-align:justify">In post-marketing safety surveillance, isolated, idiosyncratic cases of hypotension and/or worsening heart failure have been reported in patients with impaired cardiac function, in which a causal relationship to cinacalcet could not be completely excluded and may be mediated by reductions in serum calcium levels. Clinical trial data showed hypotension occurred in 7% of cinacalcet-treated patients, 12% of placebo-treated patients, and heart failure occurred in 2% of patients receiving cinacalcet or placebo.</p><p style="text-align:justify"><strong>General</strong></p><p style="text-align:justify">Adynamic bone disease may develop if PTH levels are chronically suppressed below approximately 1.5 times the upper limit of normal with the iPTH assay. If PTH levels decrease below the recommended target range in patients treated with cinacalcet, the dose of <em>Cinac </em>and/or vitamin D sterols should be reduced or therapy discontinued.</p><p style="text-align:justify"><strong>Testosterone levels</strong></p><p style="text-align:justify">Testosterone levels are often below the normal range in patients with end-stage renal disease. In a clinical study of ESRD patients on dialysis, free testosterone levels decreased by a median of 31.3% in the cinacalcet-treated patients and by 16.3% in the placebo-treated patients after 6 months of treatment. An open-label extension of this study showed no further reductions in free and total testosterone concentrations over a period of 3 years in cinacalcet-treated patients. The clinical significance of these reductions in serum testosterone is unknown.</p><p style="text-align:justify"><strong>Hepatic impairment</strong></p><p style="text-align:justify">Due to the potential for 2 to 4 fold higher plasma levels of cinacalcet in patients with moderate to severe hepatic impairment (Child-Pugh classification), <em>Cinac </em>should be used with caution in these patients and treatment should be closely monitored (see sections 4.2 and 5.2).</p><p style="text-align:justify"><strong>Lactose</strong></p><p style="text-align:justify">Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Cinacalcet is metabolised in part by the enzyme CYP3A4. Co-administration of 200 mg bid ketoconazole, a strong inhibitor of CYP3A4, caused an approximate 2-fold increase in cinacalcet levels. Dose adjustment of <em>Cinac </em>may be required if a patient receiving cinacalcet initiates or discontinues therapy with a strong inhibitor (e.g. ketoconazole, itraconazole, telithromycin, voriconazole, ritonavir) or inducer (e.g. rifampicin) of this enzyme.</p><p style="text-align:justify"><em>In vitro </em>data indicate that cinacalcet is in part metabolised by CYP1A2. Smoking induces CYP1A2; the clearance of cinacalcet was observed to be 36-38% higher in smokers than non-smokers. The effect of CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin) on cinacalcet plasma levels has not been studied. Dose adjustment may be necessary if a patient starts or stops smoking or when concomitant treatment with strong CYP1A2 inhibitors is initiated or discontinued.</p><p style="text-align:justify"><em><u>Calcium carbonate: </u></em>Co-administration of calcium carbonate (single 1,500 mg dose) did not alter the pharmacokinetics of cinacalcet.</p><p style="text-align:justify"><em><u>Sevelamer: </u></em>Co-administration of sevelamer (2400 mg tid) did not affect the pharmacokinetics of cinacalcet.</p><p style="text-align:justify"><em><u>Pantoprazole</u>: </em>Co-administration of pantoprazole (80 mg od) did not alter the pharmacokinetics of cinacalcet.</p><p style="text-align:justify">Effect of cinacalcet on other medications</p><p style="text-align:justify">Medicinal products metabolised by the enzyme P450 2D6 (CYP2D6): Cinacalcet is a strong inhibitor of CYP2D6. Dose adjustments of concomitant medicinal products may be required when <em>Cinac </em>is administered with individually titrated, narrow therapeutic index substances that are predominantly metabolised by CYP2D6 (e.g., flecainide, propafenone, metoprolol, desipramine, nortriptyline, clomipramine).</p><p style="text-align:justify"><em><u>Desipramine: </u></em>Concurrent administration of 90 mg cinacalcet once daily with 50 mg desipramine, a tricyclic antidepressant metabolised primarily by CYP2D6, significantly increased desipramine exposure 3.6-fold (90 % CI 3.0, 4.4) in CYP2D6 extensive metabolisers.</p><p style="text-align:justify"><em><u>Warfarin: </u></em>Multiple oral doses of cinacalcet did not affect the pharmacokinetics or pharmacodynamics (as measured by prothrombin time and clotting factor VII) of warfarin.</p><p style="text-align:justify">The lack of effect of cinacalcet on the pharmacokinetics of R-and S-warfarin and the absence of auto- induction upon multiple dosing in patients indicates that cinacalcet is not an inducer of CYP3A4, CYP1A2 or CYP2C9 in humans.</p><p style="text-align:justify"><em><u>Midazolam: </u></em>Co-administration of cinacalcet (90 mg) with orally administered midazolam (2 mg), a CYP3A4 and CYP3A5 substrate, did not alter the pharmacokinetics of midazolam. These data suggest that cinacalcet would not affect the pharmacokinetics of those classes of medicines that are metabolized by CYP3A4 and CYP3A5, such as certain immunosuppressants, including cyclosporine and tacrolimus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Pregnancy</strong></p><p style="text-align:justify">There are no clinical data from the use of cinacalcet in pregnant women. Animal studies do not indicate direct harmful effects with respect to pregnancy, parturition or postnatal development. No embryonal/foetal toxicities were seen in studies in pregnant rats and rabbits with the exception of decreased foetal body weights in rats at doses associated with maternal toxicities (see section 5.3). <em>Cinac </em>should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p style="text-align:justify"><strong>Breast-feeding</strong></p><p style="text-align:justify">It is not known whether cinacalcet is excreted in human milk. Cinacalcet is excreted in the milk of lactating rats with a high milk to plasma ratio. Following careful benefit/risk assessment, a decision should be made to discontinue either breast-feeding or treatment with <em>Cinac.</em></p><p style="text-align:justify"><strong>Fertility</strong></p><p style="text-align:justify">There are no clinical data relating to the effect of cinacalcet on fertility. There were no effects on fertility in animal studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">No studies on the effects on the ability to drive and use machines have been performed. However, certain adverse reactions may affect the ability to drive and use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em><strong>a)&nbsp; Summary of the safety profile</strong></em></p><p style="text-align:justify"><strong>Secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism</strong></p><p style="text-align:justify">Based on available data from patients receiving cinacalcet in placebo controlled studies and single-arm studies the most commonly reported adverse reactions were nausea and vomiting. Nausea and vomiting were mild to moderate in severity and transient in nature in the majority of patients. Discontinuation of therapy as a result of undesirable effects was mainly due to nausea and vomiting.</p><p style="text-align:justify"><em><strong>b)&nbsp;&nbsp; Tabulated list of adverse reactions</strong></em></p><p style="text-align:justify">Adverse reactions, considered at least possibly attributable to cinacalcet treatment in the placebo controlled studies and single-arm studies based on best-evidence assessment of causality are listed below using the following convention: very common (&gt; 1/10); common (&gt; 1/100 to &lt; 1/10); uncommon (&gt; 1/1,000 to &lt; 1/100); rare (&gt; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000).</p><p style="text-align:justify">Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:</p><p style="text-align:justify">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p style="text-align:justify"><strong>MedDRA system organ class</strong></p></td><td><p style="text-align:justify"><strong>Subject incidence</strong></p></td><td><p style="text-align:justify"><strong>Adverse reaction</strong></p></td></tr><tr><td><p style="text-align:justify"><em>Immune system disorders</em></p></td><td><p style="text-align:justify">*common</p></td><td><p style="text-align:justify">hypersensitivity reactions</p></td></tr><tr><td><p style="text-align:justify"><em>Metabolism and nutrition disorders</em></p></td><td><p style="text-align:justify">common</p></td><td><p style="text-align:justify">anorexia, decreased appetite</p></td></tr><tr><td><p style="text-align:justify"><em>Nervous system disorders</em></p></td><td><p style="text-align:justify">common</p></td><td><p style="text-align:justify">seizures^, dizziness, paraesthesia, headache</p></td></tr><tr><td><p style="text-align:justify"><em>Cardiac disorders</em></p></td><td><p style="text-align:justify">not known<sup>*</sup></p></td><td><p style="text-align:justify"><sup>t</sup>worsening heart failure , QT prolongation and</p><p style="text-align:justify">ventricular<sup>t</sup></p></td></tr><tr><td><p style="text-align:justify"><em>Vascular disorders</em></p></td><td><p style="text-align:justify">common</p></td><td><p style="text-align:justify">hypotension</p></td></tr><tr><td><p style="text-align:justify"><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td><p style="text-align:justify">common</p></td><td><p style="text-align:justify">upper respiratory infection, dyspnoea, cough</p></td></tr><tr><td><p style="text-align:justify"><em>Gastrointestinal disorders</em></p></td><td><p style="text-align:justify">very common</p></td><td><p style="text-align:justify">nausea, vomiting</p></td></tr><tr><td><p style="text-align:justify">&nbsp;</p></td><td><p style="text-align:justify">common</p></td><td><p style="text-align:justify">dyspepsia, diarrhoea, abdominal pain, abdominal pain - upper, constipation</p></td></tr><tr><td><p style="text-align:justify"><em>Skin and subcutaneous tissue disorders</em></p></td><td><p style="text-align:justify">common</p></td><td><p style="text-align:justify">rash</p></td></tr><tr><td><p style="text-align:justify"><em>Musculoskeletal, connective tissue and bone disorders</em></p></td><td><p style="text-align:justify">common</p></td><td><p style="text-align:justify">myalgia, muscle spasms, back pain</p></td></tr><tr><td><p style="text-align:justify"><em>General disorders and administration site conditions</em></p></td><td><p style="text-align:justify">common</p></td><td><p style="text-align:justify">asthenia</p></td></tr><tr><td><p style="text-align:justify"><em>Investigations</em></p></td><td><p style="text-align:justify">common</p></td><td><p style="text-align:justify"><sup>t</sup>hypocalcaemia , hyperkalaemia,</p><p style="text-align:justify"><sup>t</sup>reduced testosterone levels</p></td></tr></tbody></table><p style="text-align:justify"><sup>t</sup> see section 4.4</p><p style="text-align:justify">*see section c</p><p style="text-align:justify"><strong><em>c)&nbsp; </em></strong><strong><em>Description of selected adverse reactions </em></strong><strong>Hypersensitivity reactions</strong></p><p style="text-align:justify">Hypersensitivity reactions including angioedema and urticaria have been identified during post-marketing use of cinacalcet. The frequencies of the individual preferred terms including angioedema and urticaria cannot be estimated from available data.</p><p style="text-align:justify"><strong>Hypotension and/or worsening heart failure</strong></p><p style="text-align:justify">There have been reports of idiosyncratic cases of hypotension and/or worsening heart failure in cinacalcet- treated patients with impaired cardiac function in post-marketing safety surveillance, the frequencies of which cannot be estimated from available data.</p><p style="text-align:justify"><strong>QT prolongation and ventricular arrhythmia secondary to hypocalcaemia</strong></p><p style="text-align:justify">QT prolongation and ventricular arrhythmia secondary to hypocalcaemia have been identified during postmarketing use of cinacalcet, the frequencies of which cannot be estimated from available data (see section 4.4).</p><p style="text-align:justify"><em><strong>d)&nbsp; Paediatric population</strong></em></p><p style="text-align:justify">Cinacalcet is not indicated for use in paediatric patients. The safety and efficacy of cinacalcet in the paediatric population have not been established. A fatal outcome was reported in a paediatric clinical trial patient with severe hypocalcaemia (see section 4.4).</p><p style="text-align:justify"><u>Reporting of suspected adverse reactions</u></p><p style="text-align:justify">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p style="text-align:justify">To report any side effect(s):</p><ul><li style="text-align: justify;"><strong>Saudi Arabia:</strong><ul><li>The National Pharmacovigilance Centre (NPC)<ul><li>Fax: +966-11-205-7662</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa&nbsp;</li></ul></li></ul></li><li style="text-align: justify;"><strong>Other GCC States:</strong><br />Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Doses titrated up to 300 mg once daily have been safely administered to patients receiving dialysis.</p><p style="text-align:justify">Overdose of cinacalcet may lead to hypocalcaemia. In the event of overdose, patients should be monitored for signs and symptoms of hypocalcaemia, and treatment should be symptomatic and supportive. Since cinacalcet is highly protein- bound, haemodialysis is not an effective treatment for overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: Calcium homeostasis, anti-parathyroid agents. ATC code: H05BX01.</p><p style="text-align:justify"><strong>Mechanism of action</strong></p><p style="text-align:justify">The calcium sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH secretion. Cinacalcet is a calcimimetic agent which directly lowers PTH levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.</p><p style="text-align:justify">Reductions in PTH levels correlate with cinacalcet concentration.</p><p style="text-align:justify">After steady state is reached, serum calcium concentrations remain constant over the dosing interval.</p><p style="text-align:justify"><strong><u>Secondary&nbsp;</u></strong><strong><u>Hyperparathyroidism</u></strong></p><p style="text-align:justify">Three, 6-month, double-blind, placebo-controlled clinical studies were conducted in ESRD patients with uncontrolled secondary HPT receiving dialysis (n=1136). Demographic and baseline characteristics were representative of the dialysis patient population with secondary HPT. Mean baseline iPTH concentrations across the 3 studies were 733 and 683 pg/ml (77.8 and 72.4 pmol/l) for the cinacalcet and placebo groups, respectively. 66% of patients were receiving vitamin D sterols at study entry, and &gt; 90% were receiving phosphate binders. Significant reductions in iPTH, serum calcium- phosphorus product (Ca x P), calcium, and phosphorus were observed in the cinacalcet treated patients compared with placebo-treated patients receiving standard of care, and the results were consistent across the 3 studies. In each of the studies, the primary endpoint (proportion of patients with an iPTH &lt; 250 pg/ml (&lt; 26.5 pmol/l)) was achieved by 41%, 46%, and 35% of patients receiving cinacalcet, compared with 4%, 7%, and 6% of patients receiving placebo.</p><p style="text-align:justify">Approximately 60% of cinacalcet-treated patients achieved a &gt; 30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels. The mean reductions in serum Ca x P, calcium, and phosphorus were 14%, 7% and 8%, respectively.</p><p style="text-align:justify">Reductions in iPTH and Ca x P were maintained for up to 12 months of treatment. Cinacalcet decreased iPTH and Ca x P, calcium and phosphorus levels regardless of baseline iPTH or Ca x P level, dialysis modality (PD versus HD), duration of dialysis, and whether or not vitamin D sterols were administered.</p><p style="text-align:justify">Reductions in PTH were associated with non-significant reductions of bone metabolism markers (bone specific alkaline phosphatase, N-telopeptide, bone turnover and bone fibrosis). In post-hoc analyses of pooled data from 6 and 12 months clinical studies, Kaplan-Meier estimates of bone fracture and parathyroidectomy were lower in the cinacalcet group compared with the control group.</p><p style="text-align:justify">Investigational studies in patients with CKD and secondary HPT not undergoing dialysis indicated that cinacalcet reduced PTH levels to a similar extent as in patients with ESRD and secondary HPT receiving dialysis. However, efficacy, safety, optimal doses and treatment targets have not been established in treatment of predialytic renal failure patients. These studies show that CKD patients not undergoing dialysis treated with cinacalcet have an increased risk for hypocalcaemia compared with cinacalcet-treated ESRD patients receiving dialysis, which may be due to lower baseline calcium levels and/or the presence of residual kidney function.</p><p style="text-align:justify">EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) was a randomized, double-blind clinical study evaluating cinacalcet HCl vs. placebo for the reduction of the risk of all-cause mortality and cardiovascular events in 3,883 patients with secondary HPT and CKD receiving dialysis. The study did not meet its primary objective of demonstrating a reduction in risk of all-cause mortality or cardiovascular events including myocardial infarction, hospitalization for unstable angina, heart failure or peripheral vascular event (HR 0.93; 95% CI: 0.85, 1.02; p = 0.112). After adjusting for baseline characteristics in a secondary analysis, the HR for the primary composite endpoint was 0.88; 95% CI: 0.79, 0.97.</p><p style="text-align:justify"><strong><u>Parathyroid carcinoma and Primary Hyperparathyroidism</u></strong></p><p style="text-align:justify">In a key study,46 patients (29 with parathyroid carcinoma and 17 with primary HPT (who had failed or had contraindications to parathyroidectomy) received cinacalcet for up to 3 years (mean of 328 days for patients with parathyroid carcinoma and mean of 347 days for patients with primary HPT). Cinacalcet was administered at doses ranging from 30 mg twice daily to 90 mg four times daily. The primary endpoint of the study was a reduction of serum calcium of &gt; 1 mg/dl (&gt; 0.25 mmol/l). In patients with parathyroid carcinoma, mean serum calcium declined from 14.1 mg/dl to 12.4 mg/dl (3.5 mmol/l to 3.1 mmol/l), while in patients with primary HPT, serum calcium levels declined from 12.7 mg/dl to 10.4 mg/dl (3.2 mmol/l to 2.6 mmol/l). Eighteen of 29 patients (62 %) with parathyroid carcinoma and 15 of 17 subjects (88 %) with primary HPT achieved a reduction in serum calcium of &gt; 1 mg/dl (&gt; 0.25 mmol/l).</p><p style="text-align:justify">In a 28 week placebo-controlled study, 67 patients with primary HPT who met criteria for parathyroidectomy on the basis of corrected total serum calcium (&gt; 11.3 mg/dl (2.82 mmol/l) but &lt; 12.5 mg/dl (3.12 mmol/l), but who were unable to undergo parathyroidectomy were included. Cinacalcet was initiated at a dose of 30 mg twice daily and titrated to maintain a corrected total serum calcium concentration within the normal range. A significantly higher percentage of cinacalcet treated patients achieved mean corrected total serum calcium concentration &lt;10.3 mg/dl (2.57 mmol/l) and &gt; 1 mg/dl (0.25 mmol/l) decrease from baseline in mean corrected total serum calcium concentration, when compared with the placebo treated patients (75.8% versus 0% and 84.8% versus 5.9% respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Absorption</u></p><p style="text-align:justify">After oral administration of <em>Cinac, </em>maximum plasma cinacalcet concentration is achieved in approximately 2 to 6 hours. Based on between-study comparisons, the absolute bioavailability of cinacalcet in fasted subjects has been estimated to be about 20-25%. Administration of <em>Cinac </em>with food results in an approximate 50 - 80% increase in cinacalcet bioavailability. Increases in plasma cinacalcet concentration are similar, regardless of the fat content of the meal.</p><p style="text-align:justify">At doses above 200 mg, the absorption was saturated probably due to poor solubility.</p><p style="text-align:justify"><u>Distribution</u></p><p style="text-align:justify">The volume of distribution is high (approximately 1000 litres), indicating extensive distribution. Cinacalcet is approximately 97% bound to plasma proteins and distributes minimally into red blood cells.</p><p style="text-align:justify">After absorption, cinacalcet concentrations decline in a biphasic fashion with an initial half-life of approximately 6 hours and a terminal half-life of 30 to 40 hours. Steady state levels of cinacalcet are achieved within 7 days with minimal accumulation. The pharmacokinetics of cinacalcet does not change over time.</p><p style="text-align:justify"><u>Biotransformation</u></p><p style="text-align:justify">Cinacalcet is metabolised by multiple enzymes, predominantly CYP3A4 and CYP1A2 (the contribution of CYP1A2 has not been characterized clinically). The major circulating metabolites are inactive.</p><p style="text-align:justify">Based on <em>in vitro </em>data, cinacalcet is a strong inhibitor of CYP2D6, but is neither an inhibitor of other CYP enzymes at concentrations achieved clinically, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 nor an inducer of CYP1A2, CYP2C19 and CYP3A4.</p><p style="text-align:justify"><u>Elimination</u></p><p style="text-align:justify">After administration of a 75 mg radiolabelled dose to healthy volunteers, cinacalcet was rapidly and extensively metabolised by oxidation followed by conjugation. Renal excretion of metabolites was the prevalent route of elimination of radioactivity. Approximately 80% of the dose was recovered in the urine and 15% in the faeces.</p><p style="text-align:justify"><u>Linearity/non-linearity</u></p><p style="text-align:justify">The AUC and Cmax of cinacalcet increase approximately linearly over the dose range of 30 to 180 mg once daily.</p><p style="text-align:justify">Pharmacokinetic/pharmacodynamic relationship(s)</p><p style="text-align:justify">Soon after dosing, PTH begins to decrease until a nadir at approximately 2 to 6 hours postdose, corresponding with cinacalcet Cmax. Thereafter, as cinacalcet levels begin to decline, PTH levels increase until 12 hours post-dose, and then PTH suppression remains approximately constant to the end of the once- daily dosing interval. PTH levels in cinacalcet clinical trials were measured at the end of the dosing interval.</p><p style="text-align:justify"><em><u>Elderly: </u></em>There are no clinically relevant differences due to age in the pharmacokinetics of cinacalcet.</p><p style="text-align:justify"><em><u>Renal Insufficiency: </u></em>The pharmacokinetic profile of cinacalcet in patients with mild, moderate, and severe renal insufficiency, and those on haemodialysis or peritoneal dialysis is comparable to that in healthy volunteers.</p><p style="text-align:justify"><em><u>Hepatic Insufficiency: </u></em>Mild hepatic impairment did not notably affect the pharmacokinetics of cinacalcet. Compared to subjects with normal liver function, average AUC of cinacalcet was approximately 2-fold higher in subjects with moderate impairment and approximately 4-fold higher in subjects with severe impairment. The mean half-life of cinacalcet is prolonged by 33% and 70% in patients with moderate and severe hepatic impairment, respectively. Protein binding of cinacalcet is not affected by impaired hepatic function. Because doses are titrated for each subject based on safety and efficacy parameters, no additional dose adjustment is necessary for subjects with hepatic impairment (see sections 4.2 and 4.4).</p><p style="text-align:justify"><em><u>Gender: </u></em>Clearance of cinacalcet may be lower in women than in men. Because doses are titrated for each subject, no additional dose adjustment is necessary based on gender.</p><p style="text-align:justify"><em><u>Paediatric Population:</u></em><em> </em>The pharmacokinetics of cinacalcet have been studied in 12 paediatric patients (617 years) with CKD receiving dialysis following a single, oral, 15 mg dose. Mean AUC and Cmax values (23.5 (range 7.22 to 77.2) ng*hr/ml and 7.26 (range 1.80 to 17.4) ng/ml, respectively) were within approximately 30% of the means for AUC and Cmax values observed in a single study in healthy adults following a single 30 mg dose (33.6 (range 4.75 to 66.9) ng*hr/ml and 5.42 (range 1.41 to 12.7) ng/ml, respectively). Due to the limited data in paediatric subjects, the potential for higher exposures in the lighter/younger relative to heavier/older paediatric subjects for a given dose of cinacalcet cannot be excluded. The pharmacokinetics in paediatric subjects after multiple doses has not been studied.</p><p style="text-align:justify"><em><u>Smoking: </u></em>Clearance of cinacalcet is higher in smokers than in non-smokers, likely due to induction of CYP1A2-mediated metabolism. If a patient stops or starts smoking, cinacalcet plasma levels may change and dose adjustment may be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Cinacalcet was not teratogenic in rabbits when given at a dose of 0.4 times, on an AUC basis, the maximum human dose for secondary HPT (180 mg daily). The non-teratogenic dose in rats was 4.4 times, on an AUC basis, the maximum dose for secondary HPT. There were no effects on fertility in males or females at exposures up to 4 times a human dose of 180 mg/day (safety margins in the small population of patients administered a maximum clinical dose of 360 mg daily would be approximately half those given above).</p><p style="text-align:justify">In pregnant rats, there were slight decreases in body weight and food consumption at the highest dose. Decreased foetal weights were seen in rats at doses where dams had severe hypocalcaemia. Cinacalcet has been shown to cross the placental barrier in rabbits.</p><p style="text-align:justify">Cinacalcet did not show any genotoxic or carcinogenic potential. Safety margins from the toxicology studies are small due to the dose-limiting hypocalcaemia observed in the animal models. Cataracts and lens opacities were observed in the repeat dose rodent toxicology and carcinogenicity studies, but were not observed in dogs or monkeys or in clinical studies where cataract formation was monitored. Cataracts are known to occur in rodents as a result of hypocalcaemia.</p><p style="text-align:justify">In <em>in vitro </em>studies, IC50 values for the serotonin transporter and KATP channels were found to be 7 and 12 fold greater, respectively, than the EC50 for the calcium-sensing receptor obtained under the same experimental conditions. The clinical relevance is unknown, however, the potential for cinacalcet to act on these secondary targets cannot be fully excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>lactose monohydrate cellulose, microcrystalline (type 102) starch, pregelatinized (maize) crospovidone (type A) magnesium stearate talc</p><p><u>Tablet coat (</u>SheffCoat green L1171G23)</p><p>hypromellose (hypromellose 3 cP and hypromellose 6 cP) titanium dioxide (E171) lactose monohydrate triacetin/glycerol triacetate yellow iron oxide (E172) FD&amp;C Blue#2/ indigotine aluminum lake (E132)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC/Aluminium blister containing 7 tablets. Pack sizes of 4 blisters (28 tablets) per carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd. 
Hail Industrial City MODON, Street No 32 
PO Box 6979, Hail 55414 
Kingdom of Saudi Arabia
Tel: +966 11 268 7900
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>